Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic

NEW YORK, August 28, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding InterMune Inc. (NASDAQ: ITMN), Amgen, Inc. (NASDAQ: AMGN), Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK) and Medtronic, Inc. (NYSE: MDT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6042-100free.

--
InterMune Inc. Research Reports
On August 24, 2014, InterMune Inc. (InterMune) and Roche jointly announced that they have entered into a definitive merger agreement for the latter to fully acquire InterMune at a price of $74.00 per share in an all-cash transaction, which corresponds to a total transaction value of $8.3 billion on a fully diluted basis. InterMune reported that Roche's offer represents a premium of 38% to its closing price on August 22, 2014 and a premium of 63% to its unaffected closing price on August 12, 2014. According to the terms of the agreement, Roche will commence a tender offer no later than August 29, 2014, to acquire all outstanding shares of InterMune common stock, and InterMune will file a recommendation statement containing the unanimous recommendation of the Company's Board that InterMune's shareholders tender their shares to Roche. The Companies plan to close the transaction in 2014, subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions. On August 25, 2014, the Company's stock skyrocketed 35.41% to end the session at $72.85. The full research reports on InterMune are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/ITMN/report.pdf

--
Amgen, Inc. Research Reports
On August 19, 2014, Amgen Inc. (Amgen) announced the appointment of Elliott M. Levy, M.D., as the Senior Vice President, Global Development, effective September 8, 2014. Prior to joining Amgen, Elliott M. Levy was working with Bristol-Myers Squibb, where he most recently served as Senior Vice President and Head, Specialty Development. Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen, said, "Elliott brings a wealth of development and leadership experience to his new role at Amgen. His track record shows his success in leading major clinical development programs, and we're confident that he will help Amgen to serve patients by advancing the large number of potential new medicines in our late-stage pipeline." The full research reports on Amgen are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/AMGN/report.pdf

--
Johnson & Johnson Research Reports
On August 25, 2014, Johnson & Johnson (Johnson & Johnson) reported that its subsidiary Janssen Pharmaceutical Companies' affiliate Cilag GmbH International (Cilag) has acquired Covagen AG (Covagen), a privately-held, bio-pharmaceutical company specializing in the development of multispecific protein therapeutics through the FynomAb® technology platform. The Company stated that Covagen's lead product, COVA 322, a bispecific anti-tumor necrosis factor (TNF)-alpha/anti-interleukin (IL)-17A FynomAb, is in Phase 1b study for psoriasis and holds potential as a treatment for a broad range of inflammatory diseases including rheumatoid arthritis. Susan B. Dillon, Ph.D., Global Therapeutic Area Head, Immunology, Janssen Research & Development, LLC, said, "We look forward to progressing COVA 322 development, and to further expanding the potential of multispecific biologics for immunologic and other diseases." The full research reports on Johnson & Johnson are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/JNJ/report.pdf

--
Merck & Co., Inc. Research Reports
On August 13, 2014, Merck & Co., Inc. (Merck) issued a statement regarding the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices' (ACIP's) updated pneumococcal vaccine recommendations for adults 65 years of age and older. The Company stated that the recommendations call for a two vaccine regimen utilizing a dose of the pneumococcal conjugate vaccine followed by a dose of Merck's PNEUMOVAX® 23, at an interval to be determined by the ACIP, in adults 65 years of age and older who have not previously received pneumococcal vaccine. Further, ACIP also voted that these recommendations for routine use of the pneumococcal conjugate vaccine in adults 65 years of age and older should be reevaluated in 2018 and revised as needed. ACIP will continue to monitor disease trends and the impact of these new recommendations. The full research reports on Merck are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/MRK/report.pdf

--
Medtronic, Inc. Research Reports
On August 26, 2014, Medtronic, Inc. (Medtronic) announced that it has acquired Sapiens Steering Brain Stimulation (Sapiens SBS), a privately held developer of deep brain stimulation (DBS) technologies for c.$200 million in an all-cash transaction. The Company stated that the acquisition will strengthen its capabilities in an important, emerging field of medicine - the modulation of brain function. Lothar Krinke, Ph.D., Vice President and General Manager of the Brain Modulation Business at Medtronic, said, "This acquisition broadens our neuroscience leadership position with innovative brain modulation technology that, along with our comprehensive portfolio of DBS solutions, may one day transform the way physicians are able to treat patients with neurodegenerative diseases like Parkinson's disease and essential tremor." The full research reports on Medtronic are available to download free of charge at:

http://www.analystsreview.com/Aug-28-2014/MDT/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED